ff_relativeren schreef op 5 januari 2020 16:07:
1. Het duurt een aantal jaren om fase 1 en fase 2 te doorlopen.
2. Intussen gaat de kapitaalvernietiging door.
3. Nieuwe aandelenemissies en nieuwe discounts vernietigen de beurskoers.
4. Dat betekent : de komende jaren van dit aandeel afblijven.
5. Zo groot is de kans op succes niet (over een aantal jaren) :
The company’s pipeline includes:
•K-NK002: A phase 1/2 study will begin in 2020 evaluating K-NK002 as an adjunctive treatment to the current standard-of-care haploidentical hematopoietic stem cell transplantation (HSCT) with post-transplant cyclophosphamide (PTCy).
Relapse remains an issue with the PTCy protocol. The phase 1/2 study was designed based on promising clinical proof-of-concept data in 25 patients that demonstrated a reduction of long-term relapse rates from 45% in a matched contemporaneous control of patients treated with PTCy, to 8% of patients treated with PTCy and K-NK002 (Blood 2017, ASCO 2018). The 63 patient phase 1/2 study will be conducted in collaboration with the Bone Marrow Transplant Clinical Trial Network (BMT-CTN), which consists of the premier transplant clinics in the United States.
•K-NK003: A phase 1/2A study will begin in 2020 evaluating K-NK003 as a treatment for patients with relapse and refractory acute myeloid leukemia. The trial is designed based on clinical proof-of-concept data that showed a 69% complete response rate (Haplo 2018).
•Pre-clinical programs: Kiadis has multiple preclinical programs evaluating its K-NK-cell therapies for the treatment of solid tumors.
bron :
www.kiadis.com/for-investors/press-re... .